Danish diabetes care giant Novo Nordisk (NOV: N) today announced the submission to the European Medicines Agency of the Marketing Authorization Application (MAA) for the approval of faster-acting insulin aspart.
Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes. Faster-acting insulin aspart is insulin aspart (NovoRapid) in a new formulation in which two new excipients have been added to ensure early and fast absorption.
Novo Nordisk expects to file the new drug application for faster-acting insulin aspart with the US Food and Drug Administration before year-end 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze